Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Zaleplon Capsules 5mg and 10mg

Hyderabad, India | June 10, 2008 | Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Zaleplon Capsules 5mg and 10mg.

Zaleplon Capsules are the generic equivalent of King Pharmaceuticals’ Sonata® Capsules, which are indicated for the treatment of insomnia. Aurobindo is in the first line of generics and got the USFDA nod on the very first day post the expiry of the relevant patent and has already launched the product in the US market. This is Aurobindo’s 70th ANDA approval from the USFDA.

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti- Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries.

SOURCE: Aurobindo Pharma Limited
 

---